MedTrace Logo

Effect of Dabigatran on Coagulation parameters-an ex Vivo Study

NCT01112202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2012-06-06

No results posted yet for this study

Summary

Dabigatran represent a new class of promising anticoagulation agents. As an oral direct thrombin inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery. This ex vivo study is undertaken to investigate the ex-vivo effects of Pradaxa® on different coagulation parameters.

Conditions

  • Effect of Dabigatran in Laboratory Coagulation Parameters

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-02-28
Completion
2011-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01112202 on ClinicalTrials.gov